Morgan Stanley lowered the firm’s price target on Bicycle Therapeutics to $30 from $40 and keeps an Equal Weight rating on the shares. Data from last week’s R&D day show that response rates from the BT8009 monotherapy data in urothelial cancer are competitive to Padcev, and BT8009 monotherapy and combination data suggest potential for best-in-class tolerability, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCYC:
- Bicycle Therapeutics price target lowered by $3 at Needham, here’s why
- Bicycle Therapeutics price target lowered to $43 from $46 at Needham
- Bicycle Therapeutics to host research and development day
- Bicycle Therapeutics updates clinical programs at first ‘R&D Day’
- Imunon appoints Sebastien Hazard as CMO
